Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases

Journal of Bone Oncology

Volumn 1, Issue 1, 2012, Pages 24-29

  Quattrocchi, Carlo C ^a   Dell'Aia, Paola ^a   Errante, Yuri ^a   Occhicone, Filomena ^a   Longo, Daniela ^b   Virzi, Vladimir ^a   Tonini, Giuseppe ^a   Napoli, Nicola ^a   Santini, Daniele ^a   Zobel, Bruno Beomonte ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bone metastasis; Cortical bone; CT Density; Osteolytic; Trabecular bone; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE SCINTISCANNING; CALVARIA; CENTRAL VENOUS CATHETERIZATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DRUG INFUSION; DRUG MONITORING; FEMALE; FEMUR NECK; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VEIN; RETROSPECTIVE STUDY; SOLID TUMOR; TRABECULAR BONE; TREATMENT DURATION;

EID: 84864251542     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.02.001     Document Type: Article

References (45)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2002;2(8):584-93. (Pubitemid 37328925)
2. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. Journal of Clinical Oncology 2004;22(14):2942-53. (Pubitemid 41079914)
3. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. British Journal of Cancer 1977:292-8.
4. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80(Suppl. 8):1546-56. (Pubitemid 27444026)
5. Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lungand breast cancers. Journal of Orthopaedic Research 2004;22(6):1161-7.
6. Body JJ. Clinical trialsinmetastaticbreastcancertobone:past-present- future. CanadianJournalofOncology1995;5(Suppl.1):16-27.
7. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine 1996;335(24):1785-91. (Pubitemid 26412396)
8. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine 1996;334(8):488-93. (Pubitemid 26067736)
9. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose [31 intravenous pamidronate for metastatic bone pain. British Journal of Cancer 1994:554-8. (Pubitemid 24268564)
10. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double- blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11(1):59-65. (Pubitemid 23059975)
11. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo- [33 controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340(8827):1049-52.
12. Saad F, Lipton A. ZA is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU International 2005;96(7):964-9. (Pubitemid 41531396)
13. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Journal of the National Cancer Institute 2005;97(1):59-69.
14. Silverman SL. Paget disease of bone: therapeutic options. Journal of Clinical Rheumatology 2008;14(5):299-305.
15. Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of ZA 4 mg in patients with hypercalcemia of malignancy. Japanese Journal of Clinical Oncology 2005;35(1):28-33. (Pubitemid 40450552)
16. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of ZA versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. American Journal of Clinical Oncology 2005;28(1):8-16. (Pubitemid 40209317)
17. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer [STAMPEDE]: a multi-arm, multistage randomized controlled trial. BJU International 2009;103(4):464-9.
18. Langer CJ. Selected clinical trials in advanced non-small-cell lung cancer. Clinical Lung Cancer 2010;11(5):358-9.
19. Rosen LS, Gordon DH, Dugan Jr W, et al. ZA is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100(1):36-43. (Pubitemid 37553537)
20. Body JJ. Rationale for the use of bisphosphonates in osteoblastic and [39 osteolytic bone lesions. Breast 2003;12(Suppl. 2):37-44.
21. Saad F, Abrahamsson PA, Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Inter- [40 national 2009;104(11):1573-9.
22. Black DM, Delmas PD, Eastell R, et al. Once-yearly ZA for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007;356(18):1809-22.
23. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. ZA and clinical fractures and mortality after hip fracture. New England Journal of Medicine 2007; 357(18):1799-809. (Pubitemid 350044800)
24. Quattrocchi CC, Piciucchi S, Sammarra M, et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiologia Medica 2007;112(7):1049-59. (Pubitemid 350057003)
25. Quattrocchi CC, Santini D, Dell-aia P, et al. A prospective analysis of CT density measurements of bone metastases after treatment with ZA. Skeletal Radiology 2007;36(12):1121-7. (Pubitemid 350112381)
26. Amir E, Whyne C, Freedman OC, et al. Radiological changes following second-line ZA treatment in breast cancer patients with bone metastases. Clinical & Experimental Metastasis 2009;26(5):479-84.
27. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer [45 2000;88(Suppl. 12):3033-7. (Pubitemid 30413187)
28. Kohno N, Aogi K, Minami H, et al. ZA significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Journal of Clinical Oncology 2005:3314-21.
29. Eastell R, Lang T, Boonen S, et al. HORIZON Pivotal Fracture Trial. Effect of once-yearly ZA on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos International 2010;21(7):1277-85.
30. Vassiliou V, Kardamakis D, Kalogeropoulou C. Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates. Journal of Surgical Oncology 2008;98(7): 567-78.
31. Reinbold WD, Wannenmacher M, Hodapp N, Adler CP. Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. Skeletal Radiology 1989;18(7):517-21. (Pubitemid 19271295)
32. Chow E, Holden L, Rubenstein J, et al. CT evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy: a feasibility study. Radiotherapy and Oncology 2004;70(3):291-4. (Pubitemid 38520162)
33. Reinbold WD, Wannenmacher M, Hodapp N, Adler CP. Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Investigation 1999;17(8):566-74.
34. Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anatomical Record 1997;249(4): 458-68. (Pubitemid 27521594)
35. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG. Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Endocrinology and Metabolism 2007;92(1):131-6. (Pubitemid 46067520)
36. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line ZA in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Journal of Clinical Oncology 2006;24(30): 4895-900. (Pubitemid 46630917)
37. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007; 70(2):315-9. (Pubitemid 47362256)
38. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate ZA. Journal of Clinical Oncology 2005;23(22):4925-35. (Pubitemid 46223998)
39. Mountzios G, Terpos E, Syrigos K, et al. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate ZA. Translational Research 2010;155(5):247-55.
40. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 2004;15(6): 457-75. (Pubitemid 39550455)
41. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor kappaB ligand [RANKL]/osteoprotegerin [OPG] ratio is increased in severe osteolysis. American Journal of Pathology 2003;163(5):2021-31. (Pubitemid 37310032)
42. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. British Journal of Urology 1991;68(1): 74-80.
43. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer 2000;82(4):858-64. (Pubitemid 30085239)
44. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Research 2002; 62(3):917-23. (Pubitemid 34126973)
45. Roodman GD. Mechanisms of bone metastases. New England Journal of Medicine 2004;350(16):1655-64.